Trials / Completed
CompletedNCT00453492
Risedronate Sodium in Post Menopausal Osteoporosis
A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Study pn Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Risedronate Sodium (Actonel) in Administered 35mg Once a Week or 5mg Once Daily
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 246 (planned)
- Sponsor
- Sanofi · Industry
- Sex
- Female
- Age
- 55 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to compare subject satisfaction of once a week dosing of 35 mg Actonel to once daily dosing of 5 mg Actonel in postmenopausal osteoporotic women. The secondary objectives are to measure compliance (50 % drug taken), and persistence, \[and urinary NTx (N-telopeptides) (optional)\].
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | risedronate sodium |
Timeline
- Start date
- 2004-01-01
- First posted
- 2007-03-29
- Last updated
- 2008-03-11
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00453492. Inclusion in this directory is not an endorsement.